Key result
Fixed-dose atorvastatin/fenofibrate demonstrates comparable pharmacokinetics to the loose combination.
Why the study?
Does a fixed-dose combination of atorvastatin/fenofibrate 10/145 mg provide comparable pharmacokinetics and safety to a loose combination in healthy Korean participants?
RCT
Does a fixed-dose combination of atorvastatin/fenofibrate 10/145 mg provide comparable pharmacokinetics and safety to a loose combination in healthy Korean participants?
Answers are grounded in this paper and cite their sources.
A fixed-dose combination of atorvastatin/fenofibrate 10/145 mg shows comparable pharmacokinetics to the loose combination, supporting its use to improve medication adherence in mixed dyslipidemia.
were, respectively, 1.0595 (0.9565-1.1735) and 0.9530 (0.9045-1.0041) for atorvastatin; 0.9459 (0.8903-1.0243) and 0.9560 (0.9151-0.9986) for 2-OH atorvastatin; and 0.9589 (0.9020-1.0193) and 0.9861 (0.9585-1.0146) for fenofibric acid. In conclusion, the FDC of atorvastatin/fenofibrate 10/145 mg demonstrated comparable pharmacokinetics to the loose combination. The findings support its use as an alternative to improve medication adherence in patients with mixed dyslipidemia requiring dual lipid-modifying therapy. Trial Registration: Clinical Research Information Service Identifier: KCT0010666.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2026) conducted an RCT in Healthy. Fixed-dose combination of atorvastatin/fenofibrate vs. Loose combination of atorvastatin/fenofibrate 10/145 mg was evaluated on Pharmacokinetics. The fixed-dose combination of atorvastatin/fenofibrate 10/145 mg demonstrated comparable pharmacokinetics to the loose combination in healthy Korean participants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: